DK1411978T3 - Botulinum-toksin ved behandlingen eller forebyggelsen af acne - Google Patents

Botulinum-toksin ved behandlingen eller forebyggelsen af acne

Info

Publication number
DK1411978T3
DK1411978T3 DK02791543T DK02791543T DK1411978T3 DK 1411978 T3 DK1411978 T3 DK 1411978T3 DK 02791543 T DK02791543 T DK 02791543T DK 02791543 T DK02791543 T DK 02791543T DK 1411978 T3 DK1411978 T3 DK 1411978T3
Authority
DK
Denmark
Prior art keywords
botulinum toxin
acne
effects
prevention
treatment
Prior art date
Application number
DK02791543T
Other languages
Danish (da)
English (en)
Inventor
Dana L Suskind
Ann H Tilton
Mary L Caire
Original Assignee
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State filed Critical Univ Louisiana State
Application granted granted Critical
Publication of DK1411978T3 publication Critical patent/DK1411978T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02791543T 2001-07-27 2002-07-25 Botulinum-toksin ved behandlingen eller forebyggelsen af acne DK1411978T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30820501P 2001-07-27 2001-07-27
PCT/US2002/023670 WO2003011333A1 (en) 2001-07-27 2002-07-25 Botulinum toxin in the treatment or prevention of acne

Publications (1)

Publication Number Publication Date
DK1411978T3 true DK1411978T3 (da) 2009-01-05

Family

ID=23192997

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02791543T DK1411978T3 (da) 2001-07-27 2002-07-25 Botulinum-toksin ved behandlingen eller forebyggelsen af acne

Country Status (15)

Country Link
US (1) US7226605B2 (de)
EP (1) EP1411978B1 (de)
JP (1) JP4138651B2 (de)
KR (1) KR100602308B1 (de)
CN (1) CN1258381C (de)
AT (1) ATE406910T1 (de)
AU (1) AU2002355730B2 (de)
CA (1) CA2451923C (de)
CY (1) CY1108605T1 (de)
DE (1) DE60228723D1 (de)
DK (1) DK1411978T3 (de)
ES (1) ES2312651T3 (de)
NZ (1) NZ531389A (de)
PT (1) PT1411978E (de)
WO (1) WO2003011333A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
AU2003263860A1 (en) 2002-08-19 2004-03-03 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7666435B2 (en) * 2002-08-19 2010-02-23 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
CA2518155A1 (en) * 2003-03-06 2004-09-16 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9078892B2 (en) 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
CA2558676C (en) * 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
NZ592041A (en) * 2004-03-03 2012-12-21 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US6991789B2 (en) 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7897147B2 (en) 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US9314416B2 (en) 2005-03-03 2016-04-19 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
JP5368793B2 (ja) 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル ナノエマルジョンを製造および使用するための組成物および方法
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
PT1959994T (pt) 2005-12-01 2017-11-30 Univ Massachusetts Lowell Nanoemulsões botulínicas
US7824694B2 (en) 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US9061025B2 (en) 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
MX2009005727A (es) 2006-12-01 2009-08-27 Anterios Inc Nanoparticulas de entidad anfifilica.
KR20150028308A (ko) 2006-12-01 2015-03-13 안테리오스, 인코퍼레이티드 펩티드 나노입자 및 이의 용도
EP2114426A4 (de) * 2006-12-29 2010-07-21 Revance Therapeutics Inc Zusammensetzungen und verfahren zur topischen anwendung und transdermalen abgabe von botulinustoxinen, die mit polypeptid-fragmenten aus hiv-tat stabilisiert sind
MX2009007070A (es) * 2006-12-29 2009-07-10 Revance Therapeutics Inc Moleculas de transporte que utilizan los polipeptidos hiv-tat de secuencia inversa.
KR20100050443A (ko) 2007-05-31 2010-05-13 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
JP2011526302A (ja) * 2008-06-26 2011-10-06 アンテリオス， インコーポレイテッド 経皮送達
CA2774951C (en) 2009-09-24 2014-12-16 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649983A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (II)
JP6470678B2 (ja) 2012-04-13 2019-02-13 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド ニューロンの開口分泌を阻害する化合物（ｉｉ）
EP2649984A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose
EP2649985A1 (de) 2012-04-13 2013-10-16 Lipotec, S.A. Verbindungen zur Hemmung neuronaler Exozytose (III)
AU2014234190A1 (en) 2013-03-22 2015-09-10 Lipotec S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9649266B2 (en) 2014-05-01 2017-05-16 Anterios, Inc. Methods to treat, prevent, and improve skin conditions
US10485855B2 (en) * 2014-05-01 2019-11-26 Anterios, Inc. Demonstrable efficacy across or within patient populations
WO2016154020A1 (en) * 2015-03-20 2016-09-29 The Regents Of The University Of California Methods for reducing sebum production and/or excretion
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
EP3470054B1 (de) 2017-10-11 2023-09-20 Hugel Inc. Mikrostrukturformulierungstechniken für botulinumtoxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
KR20200101953A (ko) * 2017-12-20 2020-08-28 알레간 인코포레이티드 보툴리눔 독소 세포 결합 도메인 폴리펩티드 및 섬유증 연관 장애의 치료를 위한 사용 방법
WO2019226599A1 (en) * 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
US11191819B2 (en) 2018-08-28 2021-12-07 Ira Sanders Skin therapeutics
LT3660509T (lt) 2018-11-29 2022-05-10 Hugel Inc. Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4885282A (en) * 1987-07-02 1989-12-05 Thornfeldt Carl R Treatment of hyperhidrosis, ichthyosis and wrinkling
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
JPH11501517A (ja) * 1995-03-16 1999-02-09 クノル アクチエンゲゼルシャフト 細胞を製出するためおよび創傷治療用の定義された新規酵素混合物
JP2002528421A (ja) * 1998-10-27 2002-09-03 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 創傷治癒の促進方法
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20030021775A1 (en) * 2001-07-27 2003-01-30 Ramot University Authority For Applied Research & Industrial Development Ltd. Device for and method of controlled enzymatic removal and retrieval of tissue
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
AU2003263860A1 (en) * 2002-08-19 2004-03-03 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins

Also Published As

Publication number Publication date
PT1411978E (pt) 2008-11-28
CY1108605T1 (el) 2014-04-09
CN1543354A (zh) 2004-11-03
US7226605B2 (en) 2007-06-05
WO2003011333A1 (en) 2003-02-13
CA2451923A1 (en) 2003-02-13
EP1411978B1 (de) 2008-09-03
DE60228723D1 (de) 2008-10-16
KR20040030820A (ko) 2004-04-09
EP1411978A4 (de) 2005-08-17
ES2312651T3 (es) 2009-03-01
JP2004538310A (ja) 2004-12-24
AU2002355730B2 (en) 2007-09-13
CN1258381C (zh) 2006-06-07
EP1411978A1 (de) 2004-04-28
KR100602308B1 (ko) 2006-07-18
US20050074466A1 (en) 2005-04-07
ATE406910T1 (de) 2008-09-15
CA2451923C (en) 2009-10-20
JP4138651B2 (ja) 2008-08-27
NZ531389A (en) 2005-08-26

Similar Documents

Publication Publication Date Title
DK1411978T3 (da) Botulinum-toksin ved behandlingen eller forebyggelsen af acne
DE69710224T2 (de) Behandlung von neurodegenerativen zuständen mittels nimesulide
CR20220642A (es) 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8
WO2003088908A3 (en) Heterocyclo inhibitors of potassium channel function
ATE328599T1 (de) Antitumorale mittel
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
ATE288749T1 (de) Verwendung von kannabidiol als entzündunghemmende mittel
HK1085511A1 (en) Complement inhibitors from ticks
WO2002047708A3 (en) Selective cox-2 inhibition from edible plant extracts
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
TW200513271A (en) Topical treatment of skin conditions
DK0724444T3 (da) Fremgangsmåde til behandling af androgen alopecia med inhibitorer for 5-alfa-reduktase
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
DK0909556T3 (da) Rosaceae-ekstrakt som bradykininantagonist
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
BRPI0514600A (pt) métodos para a fabricação de um composto, para a purificação de um composto, para o tratamento de um indivìduo tendo uma condição neoplástica, tendo carcinoma de célula escamosa, e tendo carcinoma de célula basal, para a redução ou prevenção da ocorrência de uma condição neoplástica em um indivìduo, e para a redução de triglicerìdeos no soro em um indivìduo, composto, e, composição farmacêutica
WO2003013554A3 (en) Aromatase inhibitors from broussonetia papyrifera
DE60132008D1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
BR9906998A (pt) Método e composições para reduzir o envelhecimento dermatológico e para reduzir contusões
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
ATE256392T1 (de) Verwendung von polyaminosäurederivate als konservierungsmittel
WO2004103353A3 (en) Topical treatment of sebum related skin conditions
DE69936307D1 (de) Verringerung der homocysteinkonzentration im serum mittels allium und vitaminen
NO20003758L (no) Trekonserveringsmidler
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten